Biodexa Pharmaceuticals American Depositary Shs (BDRX) vs China SXT Pharmaceuticals (SXTC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Biodexa Pharmaceuticals American Depositary Shs is the larger company by market cap ($1.0 million vs $196,494), about 5.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BDRX | SXTC |
|---|---|---|
| Share price | $0.4602 | $0.1487 |
| Market cap | $1.01M | $196.49K |
| 1-day change | -12.13% | -56.71% |
| P/E ratio (TTM) | 0.01 | — |
| EPS (TTM) | $56.08 | $-730.40 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $52.05 | $83,760.00 |
| 52-week low | $0.45 | $0.1233 |
| Distance from 52-week high | -99.12% | -100.00% |
| Analyst consensus | none | — |
| Avg. price target upside | +1836.11% | — |
| Average volume | 3.72M | 4.71M |
| Shares outstanding | 2.20M | 1.32M |
| Employees | 11 | 56 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Biodexa Pharmaceuticals American Depositary Shs is about 5.2 times larger than China SXT Pharmaceuticals by market value ($1.01M vs $196.49K).
About Biodexa Pharmaceuticals American Depositary Shs
BDRX stock →Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan brain cancer. Its lead product candidate, Tolimidone, is a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 11 employees
About China SXT Pharmaceuticals
SXTC stock →China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers Advanced TCMP, including Directly-Oral-TCMP, and After-Soaking-Oral TCMP; Fine TCMP and Regular TCMP products; and raw medicinal material, such as SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen.
Health Care · Biotechnology: Pharmaceutical Preparations · 56 employees
BDRX vs SXTC FAQ
Which is bigger, Biodexa Pharmaceuticals American Depositary Shs or China SXT Pharmaceuticals?
Biodexa Pharmaceuticals American Depositary Shs (BDRX) is larger, with a market capitalization of $1.01M compared with $196.49K for China SXT Pharmaceuticals (SXTC).
Are Biodexa Pharmaceuticals American Depositary Shs and China SXT Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.